OncoTherapy Science Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	-823	-813	-1,285	-1,116	-2,570	-1,560	Upgrade
Depreciation & Amortization	-	-	-	-	16	49	Upgrade
Loss (Gain) From Sale of Assets	60	-	154	21	547	10	Upgrade
Other Operating Activities	1	-2	-2	-17	-3	-3	Upgrade
Change in Accounts Receivable	-2	-63	87	276	-247	-123	Upgrade
Change in Inventory	98	-4	25	131	-189	-16	Upgrade
Change in Accounts Payable	-75	21	-158	-240	385	-39	Upgrade
Change in Other Net Operating Assets	-21	46	-48	151	-12	-80	Upgrade
Operating Cash Flow	-762	-815	-1,227	-794	-2,073	-1,762	Upgrade
Capital Expenditures	-60	-	-2	-4	-456	-43	Upgrade
Other Investing Activities	-	-	-31	-16	-11	-9	Upgrade
Investing Cash Flow	-60	-	-33	-20	-467	-52	Upgrade
Issuance of Common Stock	1,456	1,178	676	-	1,478	-	Upgrade
Repurchase of Common Stock	-1	-1	-	-	-	-	Upgrade
Other Financing Activities	-56	-56	-5	95	-	-	Upgrade
Financing Cash Flow	1,399	1,121	671	95	1,478	-	Upgrade
Net Cash Flow	577	306	-589	-719	-1,062	-1,814	Upgrade
Free Cash Flow	-822	-815	-1,229	-798	-2,529	-1,805	Upgrade
Free Cash Flow Margin	-85.98%	-108.67%	-201.47%	-70.37%	-219.34%	-543.67%	Upgrade
Free Cash Flow Per Share	-2.90	-3.12	-5.78	-4.14	-13.49	-10.24	Upgrade
Cash Interest Paid	1	1	-	-	-	-	Upgrade
Cash Income Tax Paid	2	2	2	2	2	2	Upgrade
Levered Free Cash Flow	-537.38	-512.75	-937	-231.88	-1,782	-1,196	Upgrade
Unlevered Free Cash Flow	-536.75	-512.13	-937	-231.88	-1,782	-1,196	Upgrade
Change in Working Capital	-	-	-94	318	-63	-258	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.